Revenue from Contracts with Customers (Tables)

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue

The following table summarizes revenue by revenue source as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
Major Products/Service Lines (in thousands)	2022		2021		2022		2021
Product revenue, net(1)	$	217,782	$	93,562	$	397,791	$	180,881
License and royalty revenues(2)	5,941		7,502		34,812		12,692
Total revenues	$	223,723	$	101,064	$	432,603	$	193,573

________________________________

(1)The Company’s principal products include PYLARIFY, DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the same revenue recognition policies and judgments for all its principal products.

(2)The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG.

Revenue by product category on a net basis is as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2022		2021		2022		2021
DEFINITY	$	62,306	$	59,842	$	120,634	$	115,813
TechneLite	19,440		23,772		42,045		46,572
Other precision diagnostics	5,363		6,742		10,628		13,726
Total precision diagnostics	87,109		90,356		173,307		176,111
PYLARIFY	130,232		273		223,009		273
Other radiopharmaceutical oncology	928		2,539		2,255		4,039
Total radiopharmaceutical oncology	131,160		2,812		225,264		4,312
Strategic partnerships and other revenue	5,454		7,896		34,032		13,150
Total revenues	$	223,723	$	101,064	$	432,603	$	193,573